Published in Health Business Week, December 17th, 2004
The Neugene compounds targeted several EBOV genes.
These results, from extensive experiments, are the first associated with AVI's 5-year Cooperative Research and Development Agreement (CRADA) with U.S.AMRIID. Initiated in September, the CRADA covers a broad range of potential bioterror agents, including EBOV.
"The success in vivo against a lethal virus with no known treatments suggests that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.